Pfizer Receives Positive CHMP Opinion for Trumenba for Prevention of Meningococcal Group B Disease
March 24, 2017
March 24, 2017
NEW YORK, March 24 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that TRUMENBA(R) (Meningococcal Group B Vaccine) be granted marketing authorization in the European Union (EU) for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused b . . .
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that TRUMENBA(R) (Meningococcal Group B Vaccine) be granted marketing authorization in the European Union (EU) for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused b . . .